Table 4:
Estimation of azithromycin effect using multivariable time-dependent Cox models
| Relapse or subsequent neoplasm | Relapse | Subsequent neoplasm | ||||
|---|---|---|---|---|---|---|
| HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | |
| AZM exposure | 1.51 (0.90 to 2.55) |
0.12 | 0.82 (0.37 to 1.83) |
0.63 | 2.00 (1.01 to 3.99) |
0.048 |
| TBI | 1.17 (0.62 to 2.23) |
0.62 | 0.55 (0.22 to 1.40) |
0.21 | 1.96 (0.90 to 4.27) |
0.091 |
| DRI | 1.64 (1.20 to 2.24) |
0.002 | 2.07 (1.35 to 3.16) |
0.0008 | 1.53 (1.02 to 2.29) |
0.038 |
| cGVHD-t | 0.86 (0.34 to 2.15) |
0.74 | 1.28 (0.37 to 4.41) |
0.69 | 0.65 (0.18 to 2.37) |
0.52 |
| Age | 1.00 (0.98 to 1.02) |
0.91 | 0.99 (0.96 to 1.02) |
0.40 | 1.02 (0.99 to 1.04) |
0.14 |
| Sex/Male | 1.07 (0.64 to 1.79) |
0.79 | 1.06 (0.46 to 2.46) |
0.89 | 0.94 (0.50 to 1.77) |
0.86 |
| History of smoking | 1.28 (0.74 to 2.23) |
0.38 | 1.45 (0.64 to 3.33) |
0.38 | 1.08 (0.55 to 2.13) |
0.82 |
| Prior autologous HCT | 1.99 (1.03 to 3.87) |
0.041 | 4.24 (1.61 to 11.1) |
0.003 | 1.37 (0.68 to 2.77) |
0.38 |
| AZM exposure before BOS | 0.59 (0.30 to 1.17) |
0.13 | 0.85 (0.31 to 2.36) |
0.76 | 0.53 (0.23 to 1.22) |
0.14 |
HR: Hazard ratio; CI: confidence interval; TBI: Total body irradiation; ATG: antithymocyte globulin; DRI: disease risk index; cGVHD-t: time dependent occurrence of chronic graft-versus-host-disease; HCT: Hematopoietic cell transplantation; AZM: azithromycin; BOS: bronchiolitis obliterans syndrome; HR: hazard ratio; CI: confidence interval